Bayesian dose finding by jointly modelling toxicity and efficacy as time-to-event outcomes

Journal of the Royal Statistical Society. Series C: Applied Statistics

Volumn 58, Issue 5, 2009, Pages 719-736

  Yuan, Ying ^a   Yin, Guosheng ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Adaptive design; Bivariate survival function; Cure rate model; Phase I trial; Phase II trial; Survival curve

Indexed keywords

EID: 70350136475     PISSN: 00359254     EISSN: 14679876     Source Type: Journal    
DOI: 10.1111/j.1467-9876.2009.00674.x     Document Type: Article

References (23)

1. Berkson, J. Gage, R. P. (1952) Survival curve for cancer patients following treatment. J. Am. Statist. Ass., 47, 501 515.
2. Berry, D. A. (2006) Bayesian clinical trials. Nat. Rev. Drug Discov., 5, 27 36.
3. Braun, T. M. (2002) The bivariate continual reassessment method: extending the CRM to phase I trials of two competing outcomes. Contr. Clin. Trials, 23, 240 256.
4. Braun, T. M., Thall, P. F., Nguyen, H. Lima, M. (2007) Simultaneously optimizing dose and schedule of a new cytotoxic agent. Clin. Trials, 4, 113 124.
5. Braun, T. M., Yuan, Z. Thall, P. F. (2005) Determining a maximum tolerated schedule of a cytotoxic agent. Biometrics, 61, 335 343.
6. Chatterjee, N. Shih, J. (2001) A bivariate cure-mixture approach for modeling familial association in diseases. Biometrics, 57, 779 786.
7. Cheung, Y. K. Chappell, R. (2000) Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics, 56, 1177 1182.
8. Clayton, D. G. (1978) A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence. Biometrika, 65, 141 151.
9. Cox, D. R. (1972) Regression models and life-tables (with discussion). J. R. Statist. Soc. B, 34, 187 220.
10. Estey, E. H., Shen, Y. Thall, P. F. (2000) Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. Blood, 95, 72 77.
11. Gasparini, M. Eisele, J. (2000) A curve-free method for phase I clinical trials. Biometrics, 56, 609 615.
12. Gilks, W. R., Best, N. G. Tan, K. K. C. (1995) Adaptive rejection Metropolis sampling within Gibbs sampling. Appl. Statist., 44, 455 472.
13. Goodman, S. N., Zahurak, M. L. Piantadosi, S. (1995) Some practical improvements in the continual reassessment method for phase I studies. Statist. Med., 14, 1149 1161.
14. Korn, E. L., Midthune, D., Chen, T. T., Rubinstein, L. V., Christian, M. C. Simon, R. M. (1994) A comparison of two phase I trial designs. Statist. Med., 13, 1799 1806.
15. Kuk, A. Y. C. Chen, C. H. (1992) A mixture model combining logistic regression with proportional hazards regression. Biometrika, 79, 531 541.
16. Leung, D. H.-Y. Wang, Y.-G. (2002) An extension of the continual reassessment method using decision theory. Statist. Med., 21, 51 63.
17. Maller, R. A. Zhou, X. (1996) Survival Analysis with Long-term Survivors. New York : Wiley.
18. Møller, S. (1995) An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. Statist. Med., 14, 911 922.
19. Mukhopadhyay, S. (2000) Bayesian nonparametric inference on the dose level with specified response rate. Biometrics, 56, 220 226.
20. O'Quigley, J., Pepe, M. Fisher, L. (1990) Continual reassessment method: a practical design for Phase 1 clinical trials in cancer. Biometrics, 46, 33 48.
21. Storer, B. E. (1989) Design and analysis of Phase I clinical trials. Biometrics, 45, 925 937.
22. Thall, P. F. Cook, J. (2004) Dose-finding based on toxicity-efficacy trade-offs. Biometrics, 60, 684 693.
23. Yin, G., Li, Y. Ji, Y. (2006) Bayesian dose-finding in phase I/II trials using toxicity and efficacy odds ratio. Biometrics, 62, 777 784.